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OBJECTIVES We studied the impact of noncardiac comorbidity on potentially preventable hospitalizations
and mortality in elderly patients with chronic heart failure (CHF).
BACKGROUND Chronic HF disproportionately affects older individuals, who typically have extensive
comorbidity. However, little is known about how noncardiac comorbidity complicates care in
these patients.
METHODS This was a cross-sectional study of 122,630 individuals age 65 years with CHF identified
through a 5% random sample of all U.S. Medicare beneficiaries. We assessed the relationship
of the 20 most common noncardiac comorbidities to one-year potentially preventable
hospitalizations and total mortality. Preventable hospitalizations were determined by admis-
sions for ambulatory care sensitive conditions using predefined criteria.
RESULTS Sixty-five percent of the sample had at least one hospitalization, of which 50% were
potentially preventable. Exacerbations of CHF accounted for 55% of potentially preventable
hospitalizations. Nearly 40% of patients with CHF had 5 noncardiac comorbidities, and
this group accounted for 81% of the total inpatient hospital days experienced by all CHF
patients. The risk of hospitalization and potentially preventable hospitalization strongly
increased with the number of chronic conditions (both p  0.0001). After controlling for
demographic factors and other diagnoses, comorbidities that were associated consistently with
notably higher risks for CHF-preventable and all-cause preventable hospitalizations, and
mortality, included chronic obstructive pulmonary disease/bronchiectasis, renal failure,
diabetes, depression, and other lower respiratory diseases (all p  0.01).
CONCLUSIONS Noncardiac comorbidities are highly prevalent in older patients with CHF and strongly
associate with adverse clinical outcomes. Cardiologists and other providers routinely caring
for older patients with CHF may improve outcomes in this high-risk population by better
recognizing non-CHF conditions, which may complicate traditional CHF management
strategies. (J Am Coll Cardiol 2003;42:1226–33) © 2003 by the American College of
Cardiology Foundation
Despite advances in the care of individuals with chronic
heart failure (CHF), uncertainty remains about how best to
manage CHF in elderly patients with complex comorbidi-
ties (1). Although a few reports have examined the impact
of chronic disease comorbidity in elderly patients with CHF
(2–8), most of these have been limited by their use of index
See page 1234
scores rather than specific conditions to describe comorbid-
ity (7,8), or use of local, non-U.S. representative (6,8) or
non-U.S. samples (2,4,5). Brown and Cleland (2) studied a
Scottish cohort of 25,000 individuals with a hospital diag-
nosis of CHF, and evaluated the relationship of comorbidi-
ties to death and hospitalization. They concluded that
non-CHF conditions that may be overlooked during rou-
tine CHF management frequently precipitate, complicate,
or contribute to admissions. Redelmeier and colleagues (9)
demonstrated that when one serious condition is the central
focus of care, care for other chronic disorders is compro-
mised.
In this study, we examined whether noncardiac chronic
diseases influence potentially preventable hospitalizations
and mortality in Medicare beneficiaries with CHF. We
focused on individuals age 65 years because they account
for approximately 80% (10) of the one million reported
CHF-related hospitalizations (11) and 88% (12) of the
287,000 annually reported CHF deaths (11). We defined
potentially preventable hospitalizations by admissions for
ambulatory care sensitive conditions (ACSCs). Widely
viewed as an indicator of adequate primary care, ACSCs
reflect conditions for which timely and effective primary care
can reduce the risks of hospitalization by preventing condi-
tion onset, controlling an acute episodic illness, or managing
a chronic condition (13–15). We hypothesized that for
Medicare beneficiaries with CHF, the probability of pre-
ventable hospitalization due to any ACSC, and more
specifically to CHF-related ACSC, would increase with
greater numbers of noncardiac comorbidities. We also
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hypothesized that comorbidities typically responsive to reg-
ular outpatient management (such as diabetes mellitus
[DM] or chronic renal failure) would be associated with
higher probabilities of preventable hospitalization and mor-
tality. The presence of such relationships would suggest the
need for physicians caring for CHF to better recognize
non-CHF conditions that complicate management of older
individuals.
METHODS
Study design and sample population. This was a cross-
sectional analysis of U.S. Medicare beneficiaries age 65
years. We obtained data from a 5% nationally representative
random sample of Medicare beneficiaries with both Part A
(hospitalization services costs) and Part B (mainly physician
and outpatient services costs) fee-for-service coverage in
1999. This file, managed by the Centers for Medicare and
Medicaid Services (formerly the Health Care Financing
Administration), is commonly used for research purposes.
The enrollment file contains demographic information; the
claims files contain fee-for-service expenditures, health care
utilization (that is hospital and physician visits, services used
and procedures performed), and primary and secondary
inpatient and outpatient diagnosis billing data at the indi-
vidual beneficiary level for all Medicare covered services. We
combined the enrollment and claims files to develop indi-
vidual records for each beneficiary included in our sample.
We supplemented these data with county of residence data
from the 1999 Area Resource File (Health Resources and
Services Administration).
We used the Clinical Classification System (CCS) (16),
developed by the Agency for Health Research and Quality,
to identify individuals with CHF and chronic comorbidi-
ties. The CCS system clusters diagnoses and procedures
assigned by providers based on International Classification
of Diagnoses-9th revision (ICD-9) codes into clinically
homogenous categories. To be classified with CHF, bene-
ficiaries required at least two claims with CCS code 108
(ICD-9 codes 398.91, 428, 428.0, 428.1, and 428.9) for
non-hypertensive CHF, with at least one claim originating
from Medicare Part B outpatient visit data. We used the
criteria of two claims rather than one to increase the
specificity of diagnoses and to eliminate “rule out” encoun-
ters. We defined a chronic form of heart failure using CCS
code 108, rather than one that also included ICD-9 code
402.11, which is heart failure with hypertension, because we
felt this latter diagnosis better represented an acute cardio-
vascular diagnosis (one that might be coded during a
hospitalization) than a chronic disease state. Including
ICD-9 code 402.11 into our CHF definition expanded the
sample by 0.1% and insignificantly influenced results.
Therefore, we used only CCS code 108 to define our
sample.
Initially, 148,384 beneficiaries qualified as having CHF.
We excluded beneficiaries if they were age 65 years (n 
11,276), had incomplete enrollment (n  7,826) or county
data (n  80), had any non-death-related termination of
coverage during 1999 (n  2,751), were non-U.S. residents
(n  1,356), had zero-dollar claims associated with quali-
fying CCS codes (n 61), or were enrolled in managed care
during any part of 1999 (n  2,404), because these latter
patients frequently have incomplete utilization data. Our
final sample consisted of 122,630 individuals.
We used similar exclusions to create the analysis file for
all Medicare beneficiaries. Beginning with 2,055,561 ben-
eficiaries, we excluded those 65 years (n  363,564),
without parts A and B coverage for all 12 months (n 
105,017), with HMO coverage (331,591), or of non-U.S.
residence (n  16,493). Remaining were 1,285,895 Medi-
care beneficiaries, of which 122,630 (9.5%) met CHF
sample definition.
Dependent variables. Main outcomes in this analysis were
potentially preventable hospitalizations, designated as either
ACSC hospitalization due to CHF (CHF-ACSC) or any
ACSC hospitalization (ACSC), and all-cause mortality
occurring at any time in 1999. We also examined total
hospitalizations to determine the percentage potentially
preventable. On the basis of a previously published method
(17), we defined ACSCs using ICD-9 codes listed as either
a primary or secondary billing diagnosis from inpatient
hospitalization administrative claims. Examples of ACSCs
beyond CHF exacerbation include bronchopneumonia, de-
hydration, gastroenteritis, and diabetes with hyperosmolar,
nonketotic coma. Mortality was coded present when a
beneficiary had a 1999 date of death specified administratively.
Measures of noncardiac comorbidity. We characterized
Medicare beneficiaries by their number and types of non-
cardiac comorbidities. Noncardiac comorbidities were iden-
tified using CCS coding and included all conditions except
the following cardiac comorbidities: coronary atherosclero-
sis, cardiac dysrhythmias, valvular disorders, pericarditis,
endocarditis and myocarditis cardiomyopathy, and conduc-
tion disorders.
We combined a few CCS codes (such as Type 1 and 2
DM) to simplify chronic disease classification and group
clinically similar conditions (available upon request). We
identified the 20 most common noncardiac comorbidities
among CHF beneficiaries and treated these conditions as
independent variables associated with preventable hospital-
ization and mortality.
Abbreviations and Acronyms
ACSC  ambulatory care sensitive conditions
CCS  Clinical Classification System
CHF  chronic heart failure
COPD  chronic obstructive pulmonary disease
DM  diabetes mellitus
ICD-9  International Classification of Diagnoses-
9th revision
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Other independent variables. Our regression models for
preventable hospitalization and mortality included other
explanatory variables: gender, age, race, and primary pro-
vider type defined by the provider type that most filed
outpatient claims during 1999 (categorized as cardiologist;
generalist [general practice, family practice, internal medi-
cine, obstetrics/gynecology, geriatric medicine, preventive
medicine], or noncardiac specialist). We included the Deyo-
Charlson comorbidity score (18), which is a general comor-
bidity index used for case-mix adjustment, and the five
cardiac comorbidities defined here in preliminary analyses.
Because these variables did not significantly alter parameter
estimates of individual noncardiac comorbidities, however,
we excluded them from final models. Because availability of
hospitals and specialist care for chronic conditions can
influence clinical outcomes, we accounted for patients’ local
access to hospital services, physicians, and cardiovascular
physicians at the resident county level. We also evaluated
the impact of living in a Health Professional Shortage Area;
we excluded it from final models, however, because it did
not influence results.
Data analysis. We used descriptive statistics to examine
demographic characteristics and noncardiac comorbidity.
The probability of experiencing hospitalization or hospi-
talization due to CHF-ACSC or any ACSC was calcu-
lated for the entire population and by burden of noncar-
diac comorbidity. A test of linear trend tested the
hypothesis that hospitalizations were associated with
greater comorbidity.
We calculated period prevalences for the 20 most fre-
quent noncardiac comorbidities. We used multivariable
log-linear Poisson regression to assess the impact of each
noncardiac comorbidity on probability of a beneficiary
experiencing outcomes: CHF-ACSC or any ACSC hospi-
talization, and mortality, while adjusting for potential con-
founders. The Poisson regression allows for an unbiased
estimate of risk conferred by an exploratory variable on an
outcome that occurs frequently, as was the case for the three
outcomes we measured. Dummy-coded variables in the final
regression models included: age (65 to 69, 70 to 74, 75 to
79, 80 to 84, 85), gender, race (white or nonwhite),
primary provider type (cardiologist, generalist, or noncar-
diac specialist), and each of the 20 most prevalent noncar-
diac conditions. We performed age- and gender-stratified
models in preliminary analyses, but refrained from reporting
them because interactions between these variables and
comorbidities did not materially influence findings. Data
from the regression models are reported as maximum
likelihood risk ratios (RR) with 95% confidence limits,
where risk of outcome in the presence of exploratory
variable is compared to risk of outcome in the absence of
exploratory variable. We used Stata v7.0 (Stata Corporation,
College Station, Texas) and SAS v8.0 (SAS, Cary, North
Carolina) for all analyses.
RESULTS
Patient characteristics. Most CHF beneficiaries were
women (60%) and white (88%). Mean age was 79.6 years.
Although these data are consistent with demographics of
the entire Medicare population, beneficiaries with CHF
were, on average, 4.4 years older than the overall Medicare
population (19). Generalist physicians were the most fre-
quent source of care for 64,183 (52%) patients, noncardi-
ologist specialists for 38%, and cardiologists for 10% of
patients. The most common forms of cardiac comorbidity
were atherosclerotic heart disease, cardiac dysrhythmias, and
valvular disorders (Table 1).
Noncardiac comorbidities were highly prevalent (Tables 1
and 2). Thirty-nine percent of patients had 5 noncardiac
conditions, and only 4% had CHF alone. The most com-
Table 1. Characteristics of Patients Age 65 Years With CHF
Characteristics
Total Sample
n  122,630
(%)
Gender
Men 48,690 (40)
Women 73,940 (60)
Race
White 108,093 (88)
Black 10,673 (9)
Other 3,864 (3)
Age, yrs (%)
65–69 13,821 (11)
70–74 21,562 (18)
75–79 25,958 (21)
80–84 26,330 (21)
85 34,959 (29)
Primary provider type in 1999
Cardiologist 12,479 (10)
Generalist 64,183 (52)
Noncardiac specialist 45,968 (38)
Associated cardiac conditions
Coronary atherosclerosis and other related
heart disease
62,087 (51)
Cardiac dysrhythmias 50,826 (41)
Valvular disorders 26,941 (22)
Peri-, endo-, and myocarditis, cardiomyopathy 14,180 (12)
Conduction disorders 12,693 (10)
Total # of noncardiac comorbidities
0 5,122 (4)
1 12,360 (10)
2 18,204 (15)
3 19,961 (16)
4 18,599 (15)
5 15,029 (12)
6 11,283 (9)
7 7,860 (6)
8 5,418 (4)
9 3,383 (3)
10 5,411 (4)
Any inpatient stay, % (SE) 65 (0.1)
Inpatient stay for any ACSC, % (SE) 32 (0.1)
Inpatient stay for CHF ACSC, % (SE) 17 (0.1)
Mortality in 1999 22,481 (18)
ACSC  ambulatory care sensitive conditions; CHF  chronic heart failure; SE 
standard error.
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mon noncardiac conditions were: essential hypertension
(55%), DM (31%), and chronic obstructive pulmonary
disease (COPD)/bronchiectasis (26%) (Table 2). Seventy-
five percent of patients with CHF had at least one of these
three conditions, and 93% had at least one of the 20
conditions specified in Table 2.
Approximately 65% of CHF beneficiaries had at least one
hospitalization during 1999. Mean CHF-ACSC and
ACSC hospitalization rates were 17% and 32%, respectively
(Table 1). The most common ACSCs besides CHF (55%)
were pneumonia (21%), COPD exacerbation (13%), and
dehydration (5%). Death occurred in 22,481 patients (18%).
Noncardiac chronic disease burden and hospitalization
rates. Figure 1 depicts the relationship between number of
noncardiac comorbidities and probability of hospitalization.
Beneficiaries with CHF and no other comorbidities had a
mean probability of hospitalization of 35% (SE 1%). The
probability increased to 72% for five comorbidities and 94%
for 10 comorbidities (p  0.0001). Although patients
with 5 comorbidities comprised only 39% of the popula-
tion, they accounted for 81% of total hospital days.
Among beneficiaries with CHF and no comorbidities,
the probability of CHF-ACSC was 10%. This probability
increased to 19% in the presence of five comorbidities and
29% in the presence of 10 comorbidities. For any ACSC
hospitalization, the probability was 17% in patients with
CHF alone, 35% in the presence of five comorbidities, and
52% in the presence of 10 comorbidities (p  0.001 for
both CHF-ACSC and any ACSC hospitalization).
To determine whether high probabilities of ACSC hos-
pitalizations were unique to CHF beneficiaries and not
elderly patients in general, we compared risks of hospital-
ization and ACSC hospitalization in CHF beneficiaries to
risks in non-CHF beneficiaries from the overall Medicare
population, while controlling for number of comorbidities.
Relative to non-CHF beneficiaries, CHF beneficiaries had
a 1.27-fold (10 comorbidities) to 8.75-fold (no comor-
bidities) higher risk of overall hospitalization and a 3.25-
fold (10 comorbidities) to 21-fold (no comorbidities)
higher risk of any ACSC hospitalization. Non-CHF ben-
eficiaries also had close to zero percent risk for experiencing
CHF-ACSC hospitalization (data not shown).
Specific noncardiac comorbidity on CHF-ACSC and any
ACSC admissions, and total mortality. Tables 3, 4, and 5
present results of the unadjusted and adjusted Poisson
regressions to determine how each of the 20 most prevalent
conditions influenced the risk of a CHF beneficiary expe-
riencing CHF-ACSC, any ACSC, and death, respectively.
Complicated or secondary hypertension conveyed the great-
est adjusted RR of CHF-ACSC admission (RR 1.51, 95%
CI  1.45 to 1.56), followed by chronic renal failure (RR
1.43, 95% CI  1.36 to 1.50) and COPD/bronchiectasis
(RR 1.40, 95% CI  1.36 to 1.44) (Table 3).
Pulmonary conditions, including COPD/bronchiectasis,
lower respiratory disease/failure/or insufficiency, and asthma
were associated with the highest unadjusted RR of any
ACSC hospitalization in CHF beneficiaries (Table 4).
After adjustment, pulmonary conditions remained strongly
associated with ACSC hospitalization, as did essential and
complicated hypertension, late-stage cerebrovascular dis-
ease, chronic renal failure, Alzheimer’s disease/dementia,
DM, and depression/affective disorders.
Chronic lower respiratory disease/failure/insufficiency
was associated with the greatest adjusted risk for death
among our study population (RR 2.34, 95% CI  2.27 to
2.41) (Table 5). Renal failure conferred the next highest
adjusted RR (1.65, 95% CI  1.58 to 1.73). Interestingly,
some conditions (such as essential hypertension and hyper-
lipidemia) appeared “protective” for mortality, with risk
ratios significantly below 1.00.
Although not the focus of our study, the influences of
some demographic variables we used in our multivariable
models on patient outcomes were of some clinical interest.
Age, although an important determinant of mortality (RR
2.04, 95% CI 1.93 to 2.15 for those 85 relative to those
65 to 69), had only weak positive associations with CHF-
ACSC and ACSC hospitalizations. Gender and race min-
imally influenced outcomes.
Table 2. Twenty Most Common Noncardiac Chronic Disease
Conditions for Patients Age 65 Years With CHF (n 
122,630)
Chronic Disease Defined by CCS Code
% Prevalence
(n)
Essential hypertension 55 (67,211)
Diabetes mellitus 31 (38,175)
COPD and bronchiectasis 26 (32,275)
Ocular disorders (retinopathy, macular disease,
cataract, glaucoma)
24 (29,548)
Hypercholesterolemia 21 (25,219)
Peripheral and visceral atherosclerosis 16 (20,027)
Osteoarthritis 16 (19,929)
Chronic respiratory failure/insufficiency/ arrest
or other lower respiratory disease excluding
COPD/bronchiectasis
14 (17,610)
Thyroid disorders 14 (16,751)
Hypertension with complications and
secondary hypertension
11 (13,732)
Alzheimer’s disease/dementia 9 (10,839)
Depression/affective disorders 8 (9,371)
Chronic renal failure 7 (8,652)
Prostatic hyperplasia 7 (8,077)
Intravertebral injury, spondylosis, or other
chronic back disorders
7 (8,469)
Asthma 5 (6,717)
Osteoporosis 5 (6,688)
Renal insufficiency (acute and unspecified
renal failure)
4 (5,259)
Anxiety, somatoform disorders, and
personality disorders
3 (3,978)
Cerebrovascular disease, late effects 3 (3,750)
CCS  Clinical Classification System; CHF  chronic heart failure; COPD 
chronic obstructive pulmonary disease.
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DISCUSSION
Whereas burden of chronic illness complicates the manage-
ment of all seniors (19), the adverse impact of chronic
disease comorbidity on the care of elderly individuals with
CHF appears especially profound. In our sample, patients
with 5 comorbidities comprised approximately 40% of
Medicare beneficiaries with CHF but accounted for 81% of
total inpatient hospital days. Approximately 65% of patients
had at least one hospitalization. Half of these hospitaliza-
tions were regarded as potentially preventable, of which 55%
were CHF-related. Individuals with CHF, at any level of
chronic disease comorbidity, had markedly higher risks for
experiencing at least one preventable hospitalization relative
to individuals without CHF.
Although our study is the first to report trends for ACSC
hospitalizations in aged CHF patients, several reports have
identified inadequacies in primary care for older individuals
with multiple chronic illnesses (9,20). Wolff et al. (19)
demonstrated in a nonselective group of Medicare benefi-
ciaries, that chronic disease burden is strongly associated
with one’s risk of experiencing both ACSC admissions and
preventable complications incurred during hospitalization.
Recognizing that access to care powerfully predicts ACSC
hospitalizations (14), multiple comorbidities may impede
appropriate access to primary care that could forestall acute
events requiring hospitalization (19). The fact that multiple
comorbidities predispose individuals to medical undertreat-
ment supports this hypothesis (9).
Our observations of potentially preventable hospitaliza-
tions among patients with CHF are consistent with previ-
ously published data, mainly from smaller samples
(3,7,10,21,22). Vinson et al. (21) determined that among
161 patients age 70 years with index CHF hospitaliza-
tions, approximately 50% of readmissions by 90 days were
either possibly or probably preventable. Michalsen et al. (22)
studied 179 elderly patients hospitalized with decompen-
sated preexisting CHF and identified 54.2% of admissions
as preventable.
A number of reasons may explain why older CHF
Figure 1. Impact of noncardiac comorbidity burden on the annual prob-
ability of a Medicare beneficiary with chronic heart failure (n  122,630)
experiencing a hospitalization due to any cause, a preventable hospitaliza-
tion or a preventable hospitalization due to chronic heart failure (CHF).
Data are represented as mean probabilities. p  0.0001 for linear trend for
all outcomes. ACSC  ambulatory care sensitive conditions.
Table 3. Association of Noncardiac Comorbidity With Ambulatory Care Sensitive CHF
Hospitalization Among Medicare Beneficiaries With CHF
Condition
Risk Ratio (95% CI) (n  122,630)
Unadjusted Adjusted*
Chronic renal failure 1.91 (1.83–1.99) 1.43 (1.36–1.50)
Acute and unspecified renal failure 1.83 (1.74–1.93) 1.18 (1.11–1.25)
Hypertension—with complications or secondary 1.82 (1.76–1.88) 1.51 (1.45–1.56)
Lower respiratory disease, failure or insufficiency 1.57 (1.52–1.63) 1.34 (1.30–1.39)
COPD/bronchiectasis 1.49 (1.45–1.53) 1.40 (1.36–1.44)
Diabetes mellitus 1.41 (1.37–1.44) 1.33 (1.29–1.37)
Essential hypertension 1.31 (1.28–1.35) 1.23 (1.20–1.27)
Asthma 1.31 (1.23–1.39) 1.05 (1.00–1.11)
Anxiety, somatoform disorders, and personality disorders 1.22 (1.14–1.31) 1.15 (1.07–1.23)
Peripheral or visceral atherosclerosis 1.19 (1.15–1.23) 1.08 (1.04–1.11)
Depression/affective disorders 1.16 (1.10–1.21) 1.11 (1.05–1.16)
Thyroid disorders 1.05 (1.01–1.09) 1.04 (1.00–1.08)
Chronic back disorders† 1.01 (0.96–1.06) 1.00 (0.95–1.06)
Osteoarthritis 1.01 (0.97–1.05) 1.01 (0.97–1.05)
Cerebrovascular disease, late effects 0.98 (0.91–1.07) 0.91 (0.84–0.98)
Ocular disorders 0.98 (0.95–1.01) 0.96 (0.93–0.99)
Prostatic hyperplasia 0.93 (0.88–0.99) 0.92 (0.86–0.97)
Osteoporosis 0.91 (0.86–0.97) 0.93 (0.87–0.99)
Hypercholesterolemia 0.90 (0.87–0.93) 0.84 (0.81–0.87)
Alzheimer’s disease/dementia 0.82 (0.78–0.86) 0.81 (0.77–0.85)
*Adjusted for patient race (white or nonwhite), age (65–69, 70–74, 75–79, 80–84, 85) and gender, primary caring provider
type (cardiologist, generalist, non-cardiac specialist), patient’s county of residence per capita hospital beds, total physicians and
cardiovascular specialists; †Includes intravertebral injury, spondylosis, or other chronic back disorders.
CHF  chronic heart failure; CI  confidence interval; COPD  chronic obstructive pulmonary disease.
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patients with greater comorbidity may experience more
adverse events that lead to preventable hospitalizations.
These include underutilization of effective CHF therapies in
the presence of other conditions because of safety concerns
(for example, use of beta-blockers in asthma or angiotensin-
converting enzyme inhibitors in renal insufficiency), patient
nonadherence to or inability to recall complex dietary or
medication regimens, inadequate postdischarge care, failed
social support, and failure to promptly seek medical atten-
tion during symptom recurrence (21–25). Psychological
stress from chronically poor health may also predispose to
bad outcomes. Emotional stress can induce left ventricular
Table 4. Association of Noncardiac Comorbidity With Any Ambulatory Care Sensitive
Condition Hospitalization Among Medicare Beneficiaries With CHF
Condition
Risk Ratio (95% CI)
(n  122,630)
Unadjusted Adjusted*
COPD/bronchiectasis 1.92 (1.88–1.96) 1.46 (1.42–1.51)
Lower respiratory disease, failure or insufficiency 1.82 (1.77–1.86) 1.70 (1.65–1.76)
Asthma 1.54 (1.48–1.60) 1.13 (1.07–1.19)
Acute and unspecified renal failure 1.51 (1.45–1.57) 1.09 (1.02–1.16)
Chronic renal failure 1.51 (1.46–1.56) 1.22 (1.16–1.28)
Hypertension—with complications or secondary 1.44 (1.40–1.48) 1.29 (1.24–1.34)
Anxiety, somatoform disorders and personality disorders 1.35 (1.29–1.42) 1.11 (1.04–1.19)
Depression/affective disorders 1.30 (1.26–1.35) 1.17 (1.12–1.23)
Cerebrovascular disease, late effects 1.22 (1.16–1.29) 1.39 (1.30–1.48)
Diabetes mellitus 1.21 (1.18–1.23) 1.17 (1.14–1.21)
Peripheral or visceral atherosclerosis 1.20 (1.17–1.23) 1.13 (1.09–1.16)
Essential hypertension 1.18 (1.16–1.21) 1.50 (1.45–1.54)
Alzheimer’s disease/dementia 1.18 (1.14–1.22) 1.24 (1.19–1.30)
Osteoporosis 1.10 (1.05–1.15) 1.02 (0.96–1.08)
Thyroid disorders 1.05 (1.02–1.08) 0.99 (0.95–1.03)
Osteoarthritis 1.03 (1.00–1.05) 0.98 (0.94–1.01)
Chronic back disorders† 1.01 (0.97–1.05) 1.01 (0.96–1.07)
Ocular disorders 0.95 (0.92–0.97) 0.96 (0.93–0.99)
Prostatic hyperplasia 0.94 (0.90–0.98) 0.93 (0.88–0.99)
Hypercholesterolemia 0.80 (0.78–0.82) 1.09 (1.06–1.13)
*Adjusted for same variables as in Table 3. †Includes intravertebral injury, spondylosis or other chronic back disorders.
Abbreviations as in Table 2.
Table 5. Association of Noncardiac Comorbidity With Death Among Medicare Beneficiaries
With CHF
Condition
Risk Ratio (95% CI)
(n  122,630)
Unadjusted Adjusted*
Lower respiratory disease, failure or insufficiency 2.56 (2.48–2.63) 2.34 (2.27–2.41)
Acute and unspecified renal failure 2.06 (1.96–2.16) 1.46 (1.38–1.54)
Chronic renal failure 1.92 (1.84–1.99) 1.65 (1.58–1.73)
Alzheimer’s disease/dementia 1.64 (1.58–1.70) 1.24 (1.20–1.29)
Cerebrovascular disease, late effects 1.41 (1.32–1.51) 1.23 (1.15–1.31)
COPD/bronchiectasis 1.31 (1.27–1.34) 1.12 (1.09–1.16)
Depression/affective disorders 1.12 (1.07–1.18) 1.07 (1.02–1.13)
Peripheral or visceral atherosclerosis 1.03 (0.99–1.07) 0.95 (0.92–0.99)
Hypertension—with complications or secondary 0.97 (0.93–1.02) 0.94 (0.90–0.98)
Diabetes mellitus 0.94 (0.91–0.97) 1.11 (1.07–1.14)
Anxiety, somatoform disorders and personality disorders 0.89 (0.82–0.96) 0.89 (0.83–0.97)
Asthma 0.78 (0.73–0.83) 0.81 (0.75–0.86)
Osteoporosis 0.78 (0.73–0.83) 0.84 (0.79–0.90)
Thyroid disorder 0.73 (0.70–0.76) 0.81 (0.78–0.85)
Essential hypertension 0.61 (0.59–0.63) 0.70 (0.68–0.72)
Chronic back disorders† 0.60 (0.56–0.64) 0.78 (0.73–0.83)
Prostatic hyperplasia 0.59 (0.55–0.63) 0.63 (0.58–0.67)
Osteoarthritis 0.56 (0.54–0.59) 0.65 (0.62–0.68)
Ocular disorders 0.40 (0.39–0.42) 0.46 (0.44–0.48)
Hypercholesterolemia 0.33 (0.31–0.35) 0.47 (0.44–0.49)
*Adjusted for same variables as in Table 3; †Includes intravertebral injury, spondylosis, or other chronic back disorders.
Abbreviations as in Table 2.
1231JACC Vol. 42, No. 7, 2003 Braunstein et al.
October 1, 2003:1226–33 Comorbidity in the Elderly With Heart Failure
dysfunction in patients with idiopathic cardiomyopathy
(26), and in one study preceded CHF hospitalization in
49% of patients (27). Elderly patients with multiple comor-
bidities and polypharmacy are also susceptible to poor coordi-
nation of care (19) and at increased risk for experiencing
adverse drug reactions from drug-drug interactions (28). Fi-
nally, it may be that greater chronic disease burden results in
diminished physiologic reserve and hence more acute events.
In this study, we found that renal disease, hypertension,
COPD/bronchiectasis, anxiety/somatoform/and personality
disorders, and DM associate with the highest risks of ACSC
hospitalizations. The association of these comorbidities with
potentially preventable hospitalizations is clinically relevant
because these conditions are all typically responsive to effective
outpatient management, and possibly, to care coordination
with non-cardiologists. Although it remains unproven that
improving outpatient access and care integration necessarily
improves outcomes among older CHF patients with these
comorbidities, these strategies clearly target two important
indicators of healthcare quality (14).
Some of our results might seem unexpected without
further discussion. Alzheimer’s disease/dementia conferred
a lower preventable CHF hospitalization risk, but higher
overall preventable hospitalization and mortality risk. Sloan
and Taylor (29) also observed Medicare patients with
Alzheimer’s disease to have high rates of mortality and
hospitalization for conditions like pneumonia and hip frac-
ture, but low rates of hospitalization for CHF; it may be
that caregivers or chronic care institutions have high thresh-
olds for hospitalizing near-terminal patients with dementia
for CHF exacerbations. Hypertension also associated with
unexpected outcomes, conferring a higher preventable hos-
pitalization risk but lower overall mortality risk. Although
uncontrolled hypertension can frequently precipitate CHF
hospitalizations (21,22), uncomplicated hypertension may
be “protective” in the CHF setting (30,31). This may relate
to differences in prognosis between CHF due to diastolic
dysfunction with blood pressures in the “hypertensive” range
and CHF due to systolic dysfunction with blood pressures
in the low-output failure range (30). Finally, hypercholes-
terolemia appeared protective in the setting of CHF by
conferring a 53% lower mortality risk than those without
hypercholesterolemia. Several other studies have correlated
high lipoprotein levels with improved survival rates among
individuals with CHF (32,33). One proposed mechanism is
the capacity for lipoproteins to bind lipopolysaccharide, and
curtail proinflammatory cytokine production and cytokine-
induced catabolism (34). An additional explanation is a
coding artifact. Healthier patients may more likely have
hypercholesterolemia coded on an administrative billing
form than do patients with serious conditions requiring
frequent medical attention (35).
Study limitations. This study has several noteworthy lim-
itations. First, we used administrative claims data to draw
inferences about care outcomes. This precluded assessments
of heart failure etiology, ejection fraction, disease severity,
medication usage and several sociodemographic factors.
Thus, we cannot ignore the potential impact of unmeasured
confounders on our results. Because we were unable to
distinguish diastolic from systolic dysfunction, we are also
unable to conclude whether the impact of chronic disease
comorbidity on outcomes is the same for these two forms of
CHF. The lack of significant age and gender interactions
with the comorbidities we studied on outcomes provides
some suggestion that these differences are unlikely substan-
tial, given that the predominant forms of CHF for elderly
females and younger males are diastolic and systolic dys-
function, respectively.
A second limitation is that we used ICD-9 codes to
define chronic conditions. Whereas ICD-9 codings for
chronic conditions can have variable sensitivity, the speci-
ficity of this method to identify a condition is typically
exceptional, with levels exceeding 96% (36). In addition to
coding practices varying by providers and institutions, sev-
eral studies, including those that evaluated coding in pa-
tients with heart failure, suggest that severe, acute compli-
cations take coding precedence over chronic conditions,
particularly during hospitalizations (31,35). The reason for
underreporting chronic diseases may also relate to influences
of reimbursement incentives on ICD-9 coding. Although
claims-based selection and misclassification bias likely bi-
ased the prevalence rates of our chronic conditions down-
ward, we do not believe such biases invalidate the major
implications of our analysis.
Because we focused on patients age 65 years and
excluded beneficiaries enrolled in managed care, our results
may not be generalizable to the entire Medicare CHF
population. Also, because we used two CHF-coded claims
rather than one to increase the specificity of our defined
sample, we may have favorably or adversely selected a
population by excluding incident CHF cases with just one
claim. We performed a sensitivity analysis to estimate the
impact of this potential selection bias. As this resulted in
little change to probabilities of outcomes, selection bias on
these grounds appears minimal. A final study limitation is
that we did not account for time-dependent variables in our
multivariable regression models. Beneficiaries who devel-
oped incident CHF beyond year onset or who died before
year-end would have had shortened periods of risk exposure
to the outcomes we measured compared to those with CHF
for the entire 1999 study period.
Conclusions. Noncardiac comorbidity clearly complicates
CHF care and is prevalent in one form or another for over
95% of elderly individuals with CHF. These data suggest
that the health system’s current “cardiologic” approach for
managing elderly patients with CHF needs strong consid-
eration of change. Parmley (37) recently recognized this
need and outlined the growing importance for cardiologists
to better recognize the frailty of the primary population they
increasingly treat. Optimal approaches to managing elderly
patients with CHF also need clearer definition. The strin-
gent entry criteria of most randomized-controlled CHF
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treatment trials typically exclude elderly patients and those
with one or more significant comorbidities (38,39). Under-
representation of these individuals makes it difficult to
generalize findings to patients with CHF more likely to be
encountered in routine clinical practice.
In conclusion, this study highlights how noncardiac
comorbidities negatively influence individuals with CHF.
Responses from cardiologists might include increased vigi-
lance to conditions that complicate care, reorganized prac-
tices to reduce access barriers and improved communica-
tions with other providers when quality of comprehensive
care seems suboptimal. Medicare responses might include
multidisciplinary disease management teams, explicit pay-
ment for care coordination and new case-mix-adjusted
reimbursement strategies that reward cardiologists for rec-
ognizing and referring, when necessary, patients with inap-
propriately treated noncardiac conditions. Given the steady
rise in CHF incidence and prevalence in an aging popula-
tion, optimizing outcomes for this high-risk population is a
public health imperative.
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